对比增强乳腺X线摄影在乳腺不对称病变评估中的系统综述与Meta分析
该系统综述与Meta分析评估对比增强乳腺X线摄影(CEM)对乳腺X线或DBT检出不对称病变的诊断效能,重点分析无强化不对称的阴性预测值。纳入4项回顾性单中心研究,147个无强化不对称均无假阴性癌,合并NPV为0.98(95%CI 0.85-0.997),精确二项分析NPV为100%(95%下限97.5%)。强化不对称尤其肿块型及可疑非肿块强化与恶性强相关。
要点
- 无强化不对称的恶性风险极低,NPV达100%(保守95%下限97.5%),可支持随访策略。
- 强化不对称,尤其肿块型及可疑非肿块强化,与恶性强相关,需进一步评估。
- CEM对不对称病变的准确性和PPV受研究设置和患病率影响。
关键影像表现/征象
- 无强化不对称(NEA)共147个,均有明确结局,未观察到假阴性癌症。
- 强化不对称中,肿块型和可疑非肿块强化与恶性强相关。
- 准确性和阳性预测值(PPV)因研究设置和患病率而异。
诊断标准与关键数值
- 无强化不对称的合并NPV为0.98(95%CI 0.85-0.997;I²=0%)。
- 精确聚合二项分析显示NPV为100%,保守95%下限为97.5%。
- 研究水平NPV均为100%。
临床应用与阅片要点
- 对于乳腺X线/DBT检出的不对称病变,CEM无强化时恶性风险极低,可考虑随访而非立即活检。
- 出现强化尤其肿块型或可疑非肿块强化时,应警惕恶性,建议进一步活检。
- 注意研究设置和患病率可能影响PPV和准确性,需结合临床。
局限性
- 仅纳入4项回顾性单中心研究,可能存在选择偏倚。
- 样本量有限,尤其无强化不对称事件数为零。
- 研究间异质性低(I²=0%),但结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Contrast-enhanced mammography (CEM) is increasingly used to evaluate mammographic or digital breast tomosynthesis (DBT) detected asymmetries. We performed a systematic review and meta-analysis to estimate the diagnostic performance of CEM in this setting, focusing on the negative predictive value (NPV) of non-enhancing asymmetries.
MATERIALS AND METHODS: MEDLINE and Embase were searched through October 2025 for studies reporting outcomes of CEM in mammographic/DBT-detected asymmetries with histopathology and/or imaging follow-up. Study selection and data extraction were performed by two readers. Random-effects models with Hartung-Knapp adjustment were used for pooled estimates. Exact aggregated binomial confidence intervals were calculated for zero-event analyses. Risk of bias was assessed using QUADAS-2.
RESULTS: Four retrospective single-center studies met inclusion criteria. Across 147 non-enhancing asymmetries (NEAs) with definitive outcomes, no false-negative cancers were observed. Study-level NPVs were 100%. Random-effects pooling yielded an NPV of 0.98 (95% CI, 0.85-0.997; I² = 0%). Exact aggregated binomial analysis demonstrated an NPV of 100% with a conservative 95% lower bound of 97.5%. Enhancing asymmetries, particularly mass-type and suspicious non-mass enhancement, were strongly associated with malignancy. Accuracy and positive predictive value (PPV) varied by study setting and prevalence.
CONCLUSION: In appropriately selected mammographic/DBT asymmetries, absence of enhancement on CEM is associated with an extremely low malignancy risk and may support surveillance strategies, whereas enhancement markedly increases malignant probability and refines risk stratification.
引用
- Ferre R, Benefield T, Kuzmiak CM, et al. Contrast-Enhanced Mammography in the Work-up of Asymmetries: A Systematic Review and Meta-analysis. Acad Radiol. 2026. PMID: 41963229. doi:10.1016/j.acra.2026.03.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。